Lutetium 177 dotatate (Lutathera): A treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Last Updated on

January 29, 2018 – Gastroenteropancreatic neuroendocrine tumors (GEP-NET)s are a rare group of cancers with limited treatment options that affects primarily the pancreas or gastrointestinal tract of patients.  

The American Food & Drug Administration (FDA) just approved Lutetium (Lu 177) dotatate (Lutathera) for the treatment of GEP-NETs. This is the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of GEP-NETs by the FDA. Lutetium (Lu 177) dotatate (Lutathera) is indicated for adult patients with somatostatin receptor-positive GEP-NETs.This approval provides another treatment choice for patients with these rare cancers. It also demonstrates how the FDA may consider data from therapies that are used in an expanded access program to support approval for a new treatment.

GEP-NETs can be present in the pancreas and in different parts of the gastrointestinal tract such as the stomach, intestines, colon and rectum. It is estimated that approximately one out of 27,000 people are diagnosed with GEP-NETs per year. Lutetium (Lu 177) dotatate (Lutathera) is a radioactive drug that works by binding to the somatostatin receptor, which may be present on certain tumors. After binding to the receptor, the drug enters the cell allowing radiation to cause damage to the tumor cells.

The approval of Lutetium (Lu 177) dotatate (Lutathera) was supported by two clinical studies. The first was a randomized clinical trial in 229 patients with a certain type of advanced somatostatin receptor-positive GEP-NET. Patients in this trial either received Lutetium (Lu 177) dotatate (Lutathera) in combination with the drug octreotide or octreotide alone. The study measured the length of time the tumors did not grow after treatment (so-called progression-free survival). Progression-free survival was longer for patients taking Lutetium (Lu 177) dotatate (Lutathera) with octreotide compared to patients who received octreotide alone. This means the risk of tumor growth or patient death was lower for patients who received Lutathera with octreotide compared to that of patients who received only octreotide.

The second study was based on data from 1,214 patients with somatostatin receptor-positive tumors, including GEP-NETS, who received Lutetium (Lu 177) dotatate (Lutathera) at a single site in the Netherlands. Complete or partial tumor shrinkage was reported in 16 percent of a subset of 360 patients with GEP-NETs who were evaluated for response by the FDA. Patients initially enrolled in the study received Lutetium (Lu 177) dotatate (Lutathera) as part of an expanded access program. Expanded access is a way for patients with serious or immediately life-threatening diseases or conditions who lack therapeutic alternatives to gain access to investigational drugs for treatment use.

As is the case with many therapies, Lutetium (Lu 177) dotatate comes with a fair and serious array of serious adverse effects, some of which may be life threathening. Common side effects of Lutetium (Lu 177) dotatate (Lutathera) include low levels of white blood cells (lymphopenia), high levels of enzymes in certain organs (increased GGT, AST and/or ALT), vomiting, nausea, high levels of blood sugar (hyperglycemia) and low levels of potassium in the blood (hypokalemia).

Serious and possibly liefe threatening adverse effects of Lutetium (Lu 177) dotatate (Lutathera) include low levels of blood cells (myelosuppression), development of certain blood or bone marrow cancers (secondary myelodysplastic syndrome and leukemia), kidney damage (renal toxicity), liver damage (hepatotoxicity), abnormal levels of hormones in the body (neuroendocrine hormonal crises) and infertility. Lutetium (Lu 177) dotatate (Lutathera) can cause harm to a developing fetus; women should be advised of the potential risk to the fetus and to use effective contraception. Patients taking Lutetium (Lu 177) dotatate (Lutathera) are exposed to radiation. Exposure of other patients, medical personnel, and household members should be limited in accordance with radiation safety practices.

Note that Lutetium (Lu 177) dotatate (Lutathera) had already been approved by the European Medicines Agency (EMA) in September 2017.

Print Friendly, PDF & Email

 

Tags: , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion

Comment

No comments yet

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Mayo researchers recommend all women with breast cancer diagnosis under age 66 be offered genetic testing February 21, 2020
    A study by researchers at Mayo Clinic published this week in the Journal of Clinical Oncology suggests that all women with a breast cancer diagnosis under the age of 66 be offered germline genetic testing to determine if they have a gene mutation known to increase the risk of developing other cancers and cancers among […]
  • Cross-talk between enzymes that read and correct recipes in the cookbook of life February 21, 2020
    DNA is the hereditary material in humans, a unique cookbook of who we are. This is where you'll find the answer as to why you have your specific eye and hair colour, or perhaps why you sunburn easily.
  • Study finds certain genetic tests not useful in predicting heart disease risk February 21, 2020
    A Polygenic Risk Score—a genetic assessment that doctors have hoped could predict coronary heart disease (CHD) in patients—has been found not to be a useful predictive biomarker for disease risk, according to a Vanderbilt study published in the Journal of the American Medical Association.
  • Major discovery in the genetics of Down syndrome February 21, 2020
    Researchers at CHU Sainte-Justine and Université de Montréal have discovered a new mechanism involved in the expression of Down syndrome, one of the main causes of intellectual disability and congenital heart defects in children. The study's findings were published today in Current Biology.
  • MicroRNA exhibit unexpected function in driving cancer February 20, 2020
    Researchers long thought that only one strand of a double-stranded microRNA can silence genes. Though recent evidence has challenged that dogma, it's unclear what the other strand does, and how the two may be involved in cancer. New research from Thomas Jefferson University has revealed that both strands of some microRNA coordinate to act on […]
  • Ethnobotanical medicine is effective against the bacterium causing Lyme disease February 21, 2020
    A preclinical in vitro study shows that selected plant-based herbal medicines, especially Ghanaian quinine and Japanese knotweed, work better than antibiotics against the bacterium that causes Lyme disease. These findings represent an important step towards the development of treatments that might be better tolerated and more effective than the current standard of care.
  • Opportunity blows for offshore wind in China February 21, 2020
    If China is to meet and exceed its Paris Climate Agreement goal by 2030, it's going to need to find a way to increase its wind capacity. Researchers from the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) and Huazhong University of Science and Technology in China, found that offshore wind could […]
  • Alcohol-induced deaths in US February 21, 2020
    National vital statistics data from 2000 to 2016 were used to examine how rates of alcohol-induced deaths (defined as those deaths due to alcohol consumption that could be avoided if alcohol weren't involved) have changed in the US and to compare the results by demographic groups including sex, race/ethnicity, age, socioeconomic status and geographic location. […]
  • The integrated catalysts can simplify pharmaceutical manufacturing February 21, 2020
    Prof. In Su Lee and his research team from POSTECH developed catalytic platforms based on metal organic frameworks.
  • Shaping the rings of molecules February 21, 2020
    Canadian chemists discover a natural process to control the shape of 'macrocycles,' molecules of large rings of atoms, for use in pharmaceuticals and electronics.
Top